Metabolic Reprogramming And Mitochondrial Dynamics: Novel Therapeutic Perspectives For Age-Related Macular Degeneration
Our eyes, especially the part responsible for sharp central vision, the macula, require a tremendous amount of energy to function. This energy is primarily supplied by tiny powerhouses within our cells called mitochondria. As we age, these mitochondria can become damaged and less efficient, leading to a breakdown in the cell’s energy production and an increase in harmful byproducts, a process known as oxidative stress.
Recent research suggests that these mitochondrial issues are not just a consequence of age-related macular degeneration (AMD), but a central driver of the disease. When mitochondria are unhealthy, they can’t properly manage their own life cycle—processes like dividing, merging, creating new ones, or clearing out damaged ones. This leads to a buildup of dysfunctional mitochondria, further exacerbating energy shortages and oxidative stress in the retinal pigment epithelium (RPE) cells, which are crucial for vision.
Understanding these fundamental cellular changes opens up exciting new possibilities for treatment. Instead of just managing symptoms, scientists are exploring therapies that directly target these mitochondrial problems. For example, some approaches aim to boost the cell’s natural defenses against oxidative stress or improve the repair mechanisms for mitochondrial DNA, which is often damaged in AMD.
Other promising strategies involve drugs that can enhance mitochondrial function or promote the removal of faulty mitochondria. These novel therapies, some of which are already being tested, offer hope for protecting the RPE cells, preserving vision, and potentially slowing or even preventing the progression of AMD by addressing the root causes of cellular dysfunction.
Source: link to paper